文献速递骨质疏松与代谢性骨病

绝经后骨质疏松症的现代药物治疗:从单药治疗到序贯与联合策略

Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women.
PubMed 文献 · Osteoporos Int · 2026-10-01

本文为叙述性综述,总结绝经后骨质疏松症现有药物(抗骨吸收、促骨形成及双重作用药物)的疗效与局限,指出长期单药治疗存在疗程限制、安全性、反跳及骨结构恢复不完全等问题,重点讨论序贯与联合治疗策略,认为促骨形成转抗骨吸收序贯可显著提升骨密度并降低骨折风险,联合治疗(特立帕肽联合地舒单抗)骨密度增幅更大但受费用与骨折获益不确定限制,支持基于骨折风险、既往治疗和骨转换状态的目标导向个体化序贯方案。

要点

  • 促骨形成转抗骨吸收序贯可显著提升骨密度并降低骨折风险
  • 抗骨吸收转促骨形成常致暂时性骨丢失和反应减弱
  • 特立帕肽联合地舒单抗骨密度增幅优于单药但受费用等限制

核心结论

  • 当前证据支持目标导向、个体化的治疗策略,优先根据骨折风险、既往治疗和骨转换状态安排序贯方案。
  • 最佳方案通常为高危患者先予促骨形成治疗,随后以抗骨吸收药物巩固。

研究设计与样本

  • 本文为叙述性综述,检索并汇总当前骨质疏松症药物治疗尤其是序贯与联合治疗策略的证据。

主要发现

  • 促骨形成转抗骨吸收序贯可产生显著的骨密度增益并降低骨折风险。
  • 抗骨吸收转促骨形成的转换常导致暂时性骨丢失和反应减弱。
  • 特立帕肽联合地舒单抗的骨密度增幅大于单药治疗,但受费用、骨折获益不确定和潜在累积毒性限制。

关键数值与推荐

  • 长期单药治疗存在疗程限制、安全性顾虑、反跳现象和骨结构恢复不完全等局限。
  • 联合治疗(特立帕肽联合地舒单抗)骨密度增幅大于单药,但骨折获益不确定且存在潜在累积毒性。

临床怎么用

  • 对高危患者可先启动促骨形成治疗,随后以抗骨吸收药物进行序贯巩固。
  • 制定方案时应综合评估骨折风险、既往治疗史和骨转换状态,实施个体化序贯策略。

局限性

  • 本文为叙述性综述,未报告系统检索策略、样本量或定量合并分析。
  • 联合治疗的费用、骨折获益不确定和潜在累积毒性限制其广泛应用。
  • 未来需完善序贯方案、识别预测生物标志物、确定最佳疗程并开展足够把握度的骨折终点试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis is the most frequent systemic skeletal disorder characterized by an increased fracture risk and substantial global burden. While pharmacological therapies, including antiresorptive agents, anabolic agents, and dual-action agents, have demonstrated efficacy in reducing fracture risk and improving bone mineral density, long-term management remains challenging. Limitations, including treatment duration restrictions, safety concerns, rebound phenomena, and incomplete skeletal restoration, have shifted focus from prolonged monotherapy toward strategic therapeutic approaches integrating multiple agents over time. This narrative review examines current osteoporosis pharmacotherapy with emphasis on sequential and combination treatment strategies. Sequential therapy, involving strategic transitions between agents with complementary mechanisms, has emerged as optimal for maximizing and sustaining skeletal benefits. Evidence demonstrates that anabolic-to-antiresorptive sequences produce substantial bone mineral density gains and fracture risk reduction. Conversely, antiresorptive-to-anabolic transitions often result in transient bone loss and attenuated responses. Combination therapy, particularly teriparatide with denosumab, produces greater bone mineral density increases than monotherapy but remains limited by cost, uncertain fracture benefits, and potential cumulative toxicity. Current evidence supports goal-directed, individualized treatment strategies prioritizing sequencing based on fracture risk, prior therapies, and bone turnover status. Optimal regimens typically involve initial bone-forming therapy in high-risk patients, followed by antiresorptive consolidation. Future research should refine sequential protocols, identify predictive biomarkers, establish optimal durations, and conduct adequately powered fracture trials to validate strategic approaches over traditional monotherapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Rella V, Rotondo C, Barile R, et al. Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women. Osteoporos Int. 2026. PMID: 42821094. doi:10.1007/s00198-026-08236-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。